High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial
Karen Schreiber(Guy's and St Thomas' NHS Foundation Trust), Per Soelberg Sørensen(University of Copenhagen), Bjarne Laursen(University of Southern Denmark), Rikke Ratzer(University of Copenhagen), Ellen Garde(University of Copenhagen), Hartwig R. Siebner(Universität Hamburg), Jeppe Romme Christensen(Aarhus University Hospital), Lars Börnsen(University of Copenhagen), Camilla Gøbel Madsen(University of Copenhagen), Finn Sellebjerg(Danish Multiple Sclerosis Center), Pernille Iversen(University of Copenhagen), Melinda Magyari(University of Copenhagen)
Cited by 53
Related Papers
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility
|Science|2019|1.4k
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study
|The Lancet|2001|1.1k
Multiple Sclerosis Severity Score
|Neurology|2005|957